|
![]() |
|||
|
||||
OverviewAccording to a recent report from the Japanese Ministry of Health and Welfare, the mortality rate for hepatocellular carcinoma (HCC) is more than 30 per 100000 pop ulation. In addition,epidemiologists predictan increase in this figure by the year 2015, because of the rather high incidence of chronic liver diseases caused by HCY. The same situation has been observed in other Asian countries. It seems that HCC is likely to be an endemic disease, because of the higher preva lence of chronic hepatitis and liver cirrhosis caused by HBV, HCV, and/or aflatoxins in Asian and African countries. We also note that an interesting paper appeared in a recent issue of the New England Journal of Medicine describing the increase in younger HCC patients in the United States as compared with past decades. At present, silent hepatitis C infection is now smoldering in 4 million mostly unsuspecting Americans. Those carriers will be candidates for chronic liver disease, which is a pre disposing factor for the development of HCC. In Europe there are an estimated 5 million carriers. Accordingly, it is important to do all we can to reduce the prevalence of HCC not only in African and Asian countries, but also in the United States and Europe. With this perspective,last year the Japanese Society for Hepatology, in cooperation with the Ministry of Health and Welfare, initiated a national campaign to fight HCC. Full Product DetailsAuthor: K. OkitaPublisher: Springer Verlag, Japan Imprint: Springer Verlag, Japan Edition: Softcover reprint of the original 1st ed. 2000 Dimensions: Width: 15.50cm , Height: 0.60cm , Length: 23.50cm Weight: 0.195kg ISBN: 9784431679837ISBN 10: 4431679839 Pages: 107 Publication Date: 23 October 2012 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Active Availability: Manufactured on demand ![]() We will order this item for you from a manufactured on demand supplier. Table of ContentsThe Efficacy of the Ultrasonographic Screening Test for Early Detection of Hepatocellular Carcinoma and Risk Factors of HCC in Korea.- Percutaneous Ethanol Injection Therapy, Percutaneous Infarction Therapy, and Percutaneous Microwave Coagulation Therapy for Hepatocellular Carcinoma.- Percutaneous Microwave Coagulation Therapy for Hepatocellular Carcinoma.- Percutaneous Ablation of Hepatocellular Carcinoma.- Treatment with Subsegmental Transcatheter Arterial Embolization for Hepatocellular Carcinoma: Prognosis, Recurrence, and Effect on Liver Function.- Clinical Significance of Liposome-Encapsulated OK-432 Injection with Simultaneous Interventional Radiological Treatment of Hepatocellular Carcinoma Based on Experimental Analysis of Liver-Associated Lymphocytes.- Phase II Trial of Hepatic Arterial Infusion Chemotherapy Using Cisplatin and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.- Surgical Treatment of Hepatocellular Carcinoma.- Transjugular Intrahepatic Portosystemic Shunt for Patients with Hepatocellular Carcinoma.- Prevention of Hepatocarcinogenesis by Fibrosuppression.- Cancer Vaccination by B7-1-Transfected Hepatocellular Carcinoma Cells.- Clonal Deletion, A Novel Strategy of Cancer Control that Falls Between Cancer Chemoprevention and Cancer Chemotherapy: A Clinical Experience in Liver Cancer.ReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |